236 related articles for article (PubMed ID: 32701188)
1. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Cho YK; Choi MG; Choi SC; Lee KM; Kim TO; Park SH; Moon JS; Lim YJ; Kang DH; Cheon GJ; Baik GH; Kim KO; Cho KB; Jang JS; Park JJ; Son BK; Jung HK; Kim BW; Kim SK; Lee ST; Cha JM; Kim AR; Kim EJ; Park HW; Song GS
Aliment Pharmacol Ther; 2020 Sep; 52(5):789-797. PubMed ID: 32701188
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ; Son BK; Kim GH; Jung HK; Jung HY; Chung IK; Sung IK; Kim JI; Kim JH; Lee JS; Kwon JG; Park JH; Huh KC; Park KS; Park MI; Kim N; Lee OY; Jee SR; Lee SK; Youn SJ; Kim SK; Lee ST; Hong SJ; Choi SC; Kim TN; Youn YH; Park HJ; Kang MJ; Park CH; Kim BT; Youn S; Song GS; Rhee PL
Aliment Pharmacol Ther; 2019 Apr; 49(7):864-872. PubMed ID: 30843245
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
4. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study.
Park JH; Baek EK; Choi CH; Lee KH; Kim BJ; Kim JW; Kim JG; Chang SK
Surg Endosc; 2014 Jan; 28(1):235-41. PubMed ID: 23996340
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.
Cho YK; Kim JH; Kim HS; Kim TO; Oh JH; Choi SC; Moon JS; Lee SK; Jung SW; Kim SS; Jung HK; Lee SP; Cheon GJ; Park MI; Jung HY; Ko KH; Sung IK; Lee SH; Lee JY; Lee ST; Rhee PL; Kim N; Hong SJ; Kim HJ; Kim GH; Lee KJ; Kim SK; Shin WG; Lee OY
Aliment Pharmacol Ther; 2023 Jan; 57(1):72-80. PubMed ID: 36314172
[TBL] [Abstract][Full Text] [Related]
7. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Agrawal NM; Campbell DR; Safdi MA; Lukasik NL; Huang B; Haber MM
Arch Intern Med; 2000 May; 160(10):1455-61. PubMed ID: 10826458
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects.
Han S; Choi HY; Kim YH; Nam JY; Kim B; Song GS; Lim HS; Bae KS
Aliment Pharmacol Ther; 2019 Oct; 50(7):751-759. PubMed ID: 31437865
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Chen S; Liu D; Chen H; Liao A; Li F; Liu C; Li X; Li S; Zhang Y; Wang Y; Xia M; Guo Q; Miao X; Wen Z; Xu M; Yin H; Chen H; Chen M; Xiao Y
Aliment Pharmacol Ther; 2022 Jun; 55(12):1524-1533. PubMed ID: 35505467
[TBL] [Abstract][Full Text] [Related]
10. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
Avner DL; Movva R; Nelson KJ; McFarland M; Berry W; Erfling W
Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial.
Tan ND; Miao XP; Liao AJ; Liu CX; Wu H; Chen HH; Li FF; Guo QH; Li SB; Tang YP; Xia M; Liu YL; Li X; Chen HX; Liu XW; Zhang Y; Zhang ZY; Chen MH; Xiao YL
Clin Transl Gastroenterol; 2023 Jul; 14(7):e00602. PubMed ID: 37235793
[TBL] [Abstract][Full Text] [Related]
13. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease.
Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY
J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456
[TBL] [Abstract][Full Text] [Related]
14. Rapid healing of gastric ulcers with lansoprazole.
Bardhan KD; Ahlberg J; Hislop WS; Lindholmer C; Long RG; Morgan AG; Sjostedt S; Smith PM; Stig R; Wormsley KG
Aliment Pharmacol Ther; 1994 Apr; 8(2):215-20. PubMed ID: 8038354
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.
Sunwoo J; Ji SC; Oh J; Ban MS; Nam JY; Kim B; Song GS; Yu KS; Jang IJ; Lee S
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1640-1647. PubMed ID: 33131095
[TBL] [Abstract][Full Text] [Related]
16. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Russo A; Dattilo M
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.
Kim SH; Cho KB; Chun HJ; Lee SW; Kwon JG; Lee DH; Kim SG; Jung HY; Kim JW; Lee JS; Park H; Choi SC; Jee SR; Kim HS; Ko KH; Park SJ; Lee YC; Park SH; Kim AR; Kim EJ; Park HW; Kim BT; Song GS
Aliment Pharmacol Ther; 2021 Aug; 54(4):402-411. PubMed ID: 34227708
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
Tan ND; Liu XW; Liu CX; Li SB; Chen HH; Li X; Wu H; Liao AJ; Zhen YB; Shen PZ; Huo LJ; Liu HL; Shi RH; Zhang BQ; Zhang ZY; Wang JN; Zhan Q; Deng H; Shu X; Tuo BG; Wang QZ; Du SY; Qi LZ; Zhang GX; Peng Q; Wang BM; Ye B; Chen MH; Xiao YL
J Gastroenterol Hepatol; 2022 Nov; 37(11):2060-2066. PubMed ID: 36068945
[TBL] [Abstract][Full Text] [Related]
19. Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
Horikawa Y; Mizutamari H; Mimori N; Kato Y; Fushimi S; Sato S; Okubo S
Scand J Gastroenterol; 2018 Feb; 53(2):243-251. PubMed ID: 29214885
[TBL] [Abstract][Full Text] [Related]
20. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.
Takahashi N; Take Y
J Pharmacol Exp Ther; 2018 Feb; 364(2):275-286. PubMed ID: 29180359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
